| 51 |
29549929 | Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR. | 2018 Mar |
2 |
| 52 |
29551130 | Acquired Resistance to Drugs Targeting Tyrosine Kinases. | 2018 |
1 |
| 53 |
29902613 | Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. | 2018 Aug |
1 |
| 54 |
29937990 | Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. | 2018 Jun 8 |
1 |
| 55 |
29945329 | Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation. | 2018 Jun 1 |
2 |
| 56 |
30024740 | Multiplexed Quantitative MALDI MS Approach for Assessing Activity and Inhibition of Protein Kinases Based on Postenrichment Dephosphorylation of Phosphopeptides by Metal-Organic Framework-Templated Porous CeO2. | 2018 Aug 21 |
1 |
| 57 |
30069624 | Dasatinib. | 2018 |
3 |
| 58 |
30202081 | Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase. | 2018 Sep 10 |
2 |
| 59 |
30217442 | BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells. | 2018 Oct 12 |
1 |
| 60 |
30301525 | Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling. | 2018 Nov 2 |
1 |
| 61 |
30587121 | Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma. | 2018 Dec 27 |
1 |
| 62 |
30616322 | [Study on mechanism for dasatinib inhibiting PDGFR/Bcr-Abl signaling pathway in hepatic stellate cells mediated hepatic fibrosis]. | 2018 Nov 20 |
1 |
| 63 |
30705677 | NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. | 2018 |
2 |
| 64 |
27777238 | Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. | 2017 Jan 12 |
1 |
| 65 |
27848186 | Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia. | 2017 Mar |
4 |
| 66 |
27852118 | Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. | 2017 Jan |
1 |
| 67 |
28044939 | Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors. | 2017 |
1 |
| 68 |
28213007 | Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. | 2017 Feb |
1 |
| 69 |
28245378 | [Effects of PCI-32765 and Dasatinib on the Acute Lymphoblastic Leukemic Cells and Their Mechanisms]. | 2017 Feb |
2 |
| 70 |
28283735 | In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. | 2017 Apr |
1 |
| 71 |
28349229 | MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. | 2017 Aug |
1 |
| 72 |
28456613 | E-Cadherin-Mediated Cell Contact Controls the Epidermal Damage Response in Radiation Dermatitis. | 2017 Aug |
1 |
| 73 |
28544567 | Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors. | 2017 Jun 21 |
1 |
| 74 |
28556300 | Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. | 2017 Aug |
3 |
| 75 |
28599273 | Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. | 2017 Jul 4 |
1 |
| 76 |
28622336 | A knowledge-based T2-statistic to perform pathway analysis for quantitative proteomic data. | 2017 Jun |
1 |
| 77 |
28674529 | Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry. | 2017 |
2 |
| 78 |
28743118 | Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib. | 2017 |
1 |
| 79 |
28749919 | Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. | 2017 Jul |
1 |
| 80 |
28821556 | Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. | 2017 Nov 1 |
1 |
| 81 |
29067094 | Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report. | 2017 Nov |
8 |
| 82 |
29091939 | Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. | 2017 |
1 |
| 83 |
29127384 | Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. | 2017 Nov 10 |
1 |
| 84 |
29256412 | Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction. | 2017 Dec |
1 |
| 85 |
29296813 | Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. | 2017 Sep 12 |
3 |
| 86 |
26479578 | In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study. | 2016 Oct |
1 |
| 87 |
26507546 | Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. | 2016 Feb |
1 |
| 88 |
26582603 | Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. | 2016 Apr |
1 |
| 89 |
26802644 | What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature. | 2016 Jan 21 |
1 |
| 90 |
26876246 | [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia]. | 2016 Jan |
3 |
| 91 |
27044711 | A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | 2016 Jul |
3 |
| 92 |
27078848 | CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. | 2016 May 17 |
1 |
| 93 |
27347777 | Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia. | 2016 Jul |
1 |
| 94 |
27520370 | Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway. | 2016 Sep 16 |
1 |
| 95 |
27521332 | Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. | 2016 Aug |
1 |
| 96 |
27583255 | Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. | 2016 |
1 |
| 97 |
27636353 | Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting. | 2016 Oct 2 |
1 |
| 98 |
27656875 | Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature. | 2016 |
1 |
| 99 |
27803756 | Dasatinib-induced pleural effusion: Chylothorax, an option to consider. | 2016 Oct-Dec |
1 |
| 100 |
28191543 | The third-time chronic myeloid leukemia in lymphoblastic crisis with ABL1 kinase mutation induced by decitabine, dexamethason combined with nilotinib and dasatinib. | 2016 Dec 1 |
1 |